Inogen, Inc. INGN is likely to gain from a solid product portfolio and a strong revenue guidance. However, the company is currently facing global headwinds. Shares of the company have lost 44.9% compared with the industry's 20.8% decline in a year’s time. The current level also compares unfavorably with the S&P 500 index’s 30.2% decline over the same time frame. This $1.07-BILLION medical technology company currently has a Zacks Rank #3 (Hold). Inogen’s earnings are expected to grow 11.1% in the next five years. However, the company has a trailing four-quarter positive earnings surprise of 7.2%, on average. Let’s take a closer look at the factors working in favor of the company right now. Product Portfolio & Guidance Inogen’s expanding product portfolio is a key catalyst. The company provides oxygen concentrator solutions for portable and stationary use. Inogen’s flagship product, One G4, is a single-solution portable oxygen concentrator. Recently, the company launched the Inogen One G5 in the domestic business-to-business arm. In fact, the company applied for CE marking for the same and has begun shipments to international customers.Inogen, Inc Price and Consensus Inogen, Inc price-consensus-chart | Inogen, Inc QuoteManagement also confirmed plans of incorporating the Tidal Assist Ventilator directly into the Inogen One Portable Oxygen Concentrators and making the SideKick TAV product compatible with the Inogen At-Home Stationary Concentrator. Furthermore, despite a recent decline in revenues, Inogen has kept its revenue guidance intact. For 2020, Inogen continues to expect revenues of $385-$400 million, calling for 6.4-10.5% year-over-year growth, with modest growth in rental revenues for 2020 compared with that in 2019. Deterrents Inogen has been facing global headwinds of late. The company’s international business-to-business revenues fell 7.7% year over year and 5.1% at constant currency in recent times, primarily due to tender uncertainty in certain European regions and currency headwinds. Resultantly, the company now expects to report a loss per share for the first quarter of 2020. Additionally, Inogen expects 2020 EBITDA of $44-$50 million, down from the earlier projected $56-$58 million. Estimates Picture For 2020, the Zacks Consensus Estimate for revenues is pegged at $83.35 million. For adjusted earnings per share, the same stands at a loss of 10 cents. Key Picks Some better-ranked companies in the broader medical sector include Stryker Corporation SYK, Accuray Incorporated ARAY and The Cooper Companies COO, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Stryker’s long-term earnings growth is expected at 10.1%. Accuray’s fiscal fourth-quarter earnings are expected to skyrocket 150%. Cooper Companies' long-term earnings growth is projected at 10.7%. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.Click here for the 6 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research